SCYNEXIS, Inc (SCYX)

Etorro trading 970x250
SCYNEXIS, Inc (SCYX) Logo

About SCYNEXIS, Inc

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548

SCYNEXIS, Inc News and around…

Latest news about SCYNEXIS, Inc (SCYX) common stock and company :

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
20 May, 2022 Yahoo! Finance

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually. SCYNEXIS Presentation details: H.C. Wainwright Global Investm

12 Health Care Stocks Moving In Monday's After-Market Session
16 May, 2022 FinancialContent

Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of ...

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing ...

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
12 May, 2022 Yahoo! Finance

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SCYNEXIS: Q1 Earnings Insights
12 May, 2022 FinancialContent

SCYNEXIS (NASDAQ:SCYX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors ...

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
12 May, 2022 Yahoo! Finance

BREXAFEMME® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022. Expansion of the labeling to include prevention of recurrent VVC is anticipated by end of 2022.As of May 2022, BREXAFEMME was covered by commercial insurance plans representing 93 million, or 55% of commercially insured lives.SCYNEXIS initiated MARIO, a global Phase 3 study to evaluate ibrexafungerp

Earnings Scheduled For May 12, 2022
12 May, 2022 FinancialContent

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its ...

Earnings Outlook For SCYNEXIS
11 May, 2022 FinancialContent

SCYNEXIS (NASDAQ:SCYX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know ...

SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
10 May, 2022 Yahoo! Finance

Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections who were either intolerant to standard antifungal therapy or experienced refractory infections despite treatment.In the study, ibrexafungerp was generally safe and well-tolerated with findings consistent with the existing

SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
05 May, 2022 Yahoo! Finance

JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, May 12, 2022 to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2022. Conference call and webcast details: Investors (domestic): (877

SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
04 May, 2022 Yahoo! Finance

Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 yearsJERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will present new data from its ongoing FURI study of ibrexafungerp during the American College of Obstetricians and Gynecologists

The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 68% More Shares
30 Apr, 2022 Yahoo! Finance

Potential SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders may wish to note that the CEO, President & Director, Marco...

Top Buys by Directors: Taglietti's $225K Bet on SCYX
28 Apr, 2022 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Top Buys by Top Brass: Chief Executive Officer Taglietti's $225K Bet on SCYX
28 Apr, 2022 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
27 Apr, 2022 Yahoo! Finance

New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit specialty hospital.1 Interim data of the ongoing Phase 3 FURI and CARES studies of patients with invasive candidiasis and candidemia treated with ibrexafungerp is positive and consistent with previous analyses. Additional

SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
26 Apr, 2022 Yahoo! Finance

JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants were sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The total gross offering proceeds to SCYNEXIS fr

55 Biggest Movers From Friday
25 Apr, 2022 FinancialContent

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals ...

Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections
22 Apr, 2022 FinancialContent

SCYNEXIS Inc(NASDAQ: SCYX) hasannounced interim datafrom its ongoing Phase 3 FURI and CARES studies of ...

Mid-Afternoon Market Update: Dow Dips Over 800 Points; HCA Healthcare Shares Plunge
22 Apr, 2022 FinancialContent

U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 800 points on Friday. The Dow traded ...

Mid-Day Market Update: Nasdaq Down 200 Points; Blueknight Shares Spike Higher
22 Apr, 2022 FinancialContent

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 200 points on Friday. The Dow traded down ...

Mid-Morning Market Update: Markets Open Lower; Dow Tumbles 400 Points
22 Apr, 2022 FinancialContent

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 400 points on Friday. Following the market opening ...

The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
22 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus WHO Backs Pfizer's Oral ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Apr, 2022 FinancialContent

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 94.7% to $2.2 during Friday's pre-market session. The company's ...

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
22 Apr, 2022 Yahoo! Finance

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants are being sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The gross offering proceeds to SCYNEXIS from this offering

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
22 Apr, 2022 Yahoo! Finance

Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting.Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafungerp into a broad antifungal franchise.SCYNEXIS is presenting the fourth interim analysis from FURI and the second interim analysis from CARES during the 32nd European Congress of Clinical Microbiology and Infectious Diseases (E

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
22 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Traders ready for another busy day of investing will want to know all about the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

22 Stocks Moving in Friday's Pre-Market Session
22 Apr, 2022 FinancialContent

Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and ...

12 Health Care Stocks Moving In Thursday's After-Market Session
21 Apr, 2022 FinancialContent

Gainers Pyxis Oncology (NASDAQ:PYXS) stock moved upwards by 14.0% to $3.02 during Thursday's after-market session. Pyxis Oncology's ...

Why Scynexis Shares Are Falling During Thursday's After-Hours Session
21 Apr, 2022 FinancialContent

SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the ...

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
21 Apr, 2022 Yahoo! Finance

JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. SCYNEXIS intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock and warrants offered

SCYNEXIS, Inc (SCYX) is a NASDAQ Common Stock listed in , ,

970x250